Field composites
Anand 53 years · CEO · specialty-shift decision in progress
Runs a 600-bed chain across three cities. The board has approved a 200-bed expansion, and the capex committee is split: allocate to oncology and cardiac units commanding ARPOB of ₹72,000–₹85,000, or stay general-multi-specialty at ₹42,000–₹55,000. The difference is not just revenue per bed. It is the doctor-acquisition cost, equipment amortization, regulatory certification timeline (NABH oncology versus general), and the payer-mix that each specialty attracts.
Anand's composite-modelled friction is the doctor-revenue-share structure. Oncology and cardiac consultants command 30–40% revenue-share agreements at the senior-specialist tier. The ARPOB uplift from specialty-shift is real — but it is partially consumed by the doctor compensation structure, which does not appear in the headline ARPOB number disclosed quarterly. The EBITDA margin on a specialty bed after doctor-share is the number that decides the expansion. It is not the number that gets announced.
Priya 38 years · Insurer strategy lead · empanelment + reimbursement
Manages the hospital-network empanelment for a large insurer whose covered lives are concentrated in corporate-employed TPA payers. The composite-modelled tension: listed hospital chains with oncology and cardiac orientation price empanelment negotiations on their high-ARPOB specialty mix, but Priya's TPA payer-mix skews toward elective orthopedic, mother-and-child, and general-medicine claims — segments where the chain's ARPOB is structurally lower.
The reimbursement rate that makes sense for oncology (at ₹72,000 ARPOB) produces a margin squeeze when applied to a hospital with 60% occupancy in general-multi-specialty. Priya's constraint: Ayushman Bharat reimbursement rates cap many empanelled procedures at levels that listed chains price below cost in high-ARPOB-specialty hospitals. The fraction of beds a chain dedicates to Ayushman — undisclosed in quarterly filings — determines how much of its occupancy is margin-dilutive.
Vikram 48 years · Investment banker · listed healthcare M&A pipeline
Running the valuation framework for a mid-market hospital chain acquisition. The M&A pipeline is active: announced bed counts and revenue growth rates are the buy-side headline. The integration reality surfaces in three structural items:
- Time-from-commissioning to 70%+ occupancy: 14–18 months (metro / oncology-cardiac) vs 28–42 months (Tier-2 / general-multi-specialty). The announcement-grade model assumes 18 months across the pipeline. The contribution-grade model does not survive Tier-2 general.
- Doctor-retention post-acquisition: a mid-tier chain's senior specialist roster exits at 20–35% in year-1 post-acquisition. The year-1 EBITDA-uplift projection embedded in the acquisition thesis does not price this churn. Year-3 EBITDA-uplift trajectory is the real commitment — not year-1.
- Integration EBITDA-uplift disclosure: listed hospital chains disclose synergy targets as a blended percentage of combined revenues. The specialty-mix decomposition of that synergy — which beds generate the uplift, and at what ARPOB — is not broken out. Vikram builds the specialty-EBITDA model from scratch using disclosed bed-mix and case-mix indices, not from the synergy-target slide.